CG Oncology Inc.: LifeSci Capital Reaffirms Buy Rating with 147% Upside Potential Following Promising Study Data

CG Oncology Inc. (CGON) is a biopharmaceutical company focused on the development and commercialization of oncolytic immunotherapies for the treatment of bladder cancer. The company's strategy centers on the lead product candidate CG0070, an oncolytic virus designed to selectively target cancer cells while stimulating a systemic immune response against tumors. This therapeutic approach aims to improve treatment outcomes for patients with non-muscle-invasive bladder cancer (NMIBC), which currently offers limited treatment options. Focus of Clinical...